Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12779476 | 0.84 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL12844947 | 0.82 | TRPV1 (0.47) | ALDH1A1KMT2AMAPTTP53KDM4E | |
| SCHEMBL12779456 | 0.80 | MEN1 (0.51) | MEN1ALDH1A1KMT2ALMNATP53 | |
| SCHEMBL12779461 | 0.80 | TRPV1 (0.55) | MEN1ALDH1A1KMT2ALMNATP53 | |
| SCHEMBL2072168 | 0.79 | MEN1 (0.59) | MEN1ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL2071726 | 0.76 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL4370370 | 0.75 | MEN1 (0.58) | MEN1ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL25111352 | 0.73 | LMNA (0.71) | MEN1ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL12779264 | 0.73 | NPC1 (0.56) | ALDH1A1KMT2AMAPTLMNATP53 | |
| SCHEMBL16769729 | 0.72 | KDM4E (0.76) | MEN1ALDH1A1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | TRPV1, CNR1, OPRM1 | MEN1 4455/4885ALDH1A1 1905/4885KMT2A 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.